MedTrace Logo

Similarities and Differences of Biological Therapies for Severe Asthma.

NCT04665141 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-04-27

No results posted yet for this study

Summary

This is an ambispective multicenter longitudinal observational study to evaluate the efficacy and safety profile of biological therapies in patients diagnosed with severe asthma in real life conditions.

Conditions

Interventions

BIOLOGICAL

Mepolizumab

Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.

BIOLOGICAL

Omalizumab

Omalizumab will be prescribed freely by the treating physician according to real-life conditions.

BIOLOGICAL

Reslizumab

Reslizumab will be prescribed freely by the treating physician according to real-life conditions.

BIOLOGICAL

Benralizumab

Benralizumab will be prescribed freely by the treating physician according to real-life conditions.

BIOLOGICAL

Dupilumab

Dupilumab will be prescribed freely by the treating physician according to real-life conditions.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Hospital Regional de Malaga

    collaborator OTHER

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-07
Primary Completion
2022-11-30
Completion
2022-11-30
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04665141 on ClinicalTrials.gov